Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

ADC Therapeutics (ADCT) Cost of Revenue (2020 - 2026)

ADC Therapeutics has reported Cost of Revenue over the past 7 years, most recently at $12.7 million for Q1 2026.

  • Quarterly results put Cost of Revenue at $12.7 million for Q1 2026, up 20.42% from a year ago — trailing twelve months through Mar 2026 was $44.1 million (up 1.8% YoY), and the annual figure for FY2022 was $4.6 billion, up 328714903.59%.
  • Cost of Revenue reached $12.7 million in Q1 2026 per ADCT's latest filing, up from $10.7 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $489.0 million in Q4 2022 and bottomed at $529000.0 in Q1 2022.
  • Median Cost of Revenue over the past 5 years was $10.7 million (2024), compared with a mean of $42.8 million.
  • The largest annual shift saw Cost of Revenue plummeted 96.2% in 2022 before it soared 1830.51% in 2024.
  • Over 5 years, Cost of Revenue stood at $489.0 million in 2022, then tumbled by 97.19% to $13.7 million in 2023, then dropped by 22.27% to $10.7 million in 2024, then increased by 0.14% to $10.7 million in 2025, then increased by 18.9% to $12.7 million in 2026.
  • Business Quant data shows Cost of Revenue for ADCT at $12.7 million in Q1 2026, $10.7 million in Q3 2025, and $10.1 million in Q2 2025.